What are the precautions for taking Secukinumab?

Before and during treatment with Secukinumab, patients should pay attention to adverse events such as infection, allergic reactions, inflammatory bowel disease, eczema rash, and the risk of allergy in latex-sensitive individuals. Patients should be evaluated under the guidance of a doctor before immunization and tuberculosis treatment.

1. Infection: Secukinumab may increase the risk of infection. Higher rates of infections, such as nasopharyngitis, upper respiratory tract infections, and Candida mucocutaneous infections, have been observed in secukinumab-treated subjects in clinical trials; instruct patients to seek medical advice if signs or symptoms suggestive of infection occur. If a patient develops a serious infection, the patient should be monitored closely and secukinumab should be discontinued until the infection resolves.

2. Anaphylaxis: In clinical trials, subjects receiving secukinumab experienced cases of allergic reactions and urticaria. If allergic or other severe allergic reactions occur, use should be discontinued immediately and appropriate treatment should be initiated.

3. Inflammatory bowel disease: In clinical trials of plaque psoriasis, PsA, AS and nr-axSpA, subjects treated with secukinumab experienced worsening, in some cases severe worsening. New cases of inflammatory bowel disease have emerged in clinical trials using secukinumab. Patients receiving treatment should be monitored for signs and symptoms of inflammatory bowel disease.

4. Eczematous rash: In post-marketing reports, cases of severe eczematous rash, including atopic dermatitis-like rash, dyshidrotic eczema, and erythroderma, have been reported in patients receiving secukinumab; some cases have resulted in hospitalization. The onset of eczematous rash is variable, ranging from days to months after the first dose of secukinumab. Treatment may need to be interrupted to resolve the eczematous rash. Some patients successfully treat their eczematous rash while continuing secukinumab.

5. Allergy risk for latex-sensitive individuals: The removable pen caps of secukinumab 150mg/mL Sensoready pen and secukinumab 1mL and 0.5mL prefilled syringes contain natural rubber latex, which may cause allergic reactions in people who are sensitive to latex.

6. Before tuberculosis treatment: Before starting treatment with secukinumab, assess the patient's tuberculosis infection and start treatment for latent tuberculosis. Avoid the use of secukinumab in patients with active tuberculosis infection. For patients with a past history of latent or active tuberculosis and for whom an adequate course of treatment cannot be determined, antituberculosis treatment may be considered before starting secukinumab.

7. Immunizations: Before initiating treatment with secukinumab, consider completing all age-appropriate immunizations according to current immunization guidelines. Secukinumab may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients receiving secukinumab.

The original drug secukinumab has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. SpecificationsThe price per box of 150mg/ML is around RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.